Acceptability of Depo-subQ in Uniject, Now Called "Sayana Press"

Sayana Press, a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in the Uniject injection system, has the potential to be a valuable innovation in family planning service delivery because its prefilled design may overcome logistic and safety challenges in delivering intramuscular DMPA. The ultimate success of Sayana Press hinges on it being affordable and acceptable to family planning clients, providers, and decision makers.

File:

English (665.48k)

Year:

2013

Organization:

FHI 360

Languages:

English

This website is made possible by the support of the American People through the United States Agency for International Development (USAID) under the Knowledge SUCCESS (Strengthening Use, Capacity, Collaboration, Exchange, Synthesis, and Sharing) Project. Knowledge SUCCESS is supported by USAID’s Bureau for Global Health, Office of Population and Reproductive Health and led by the Johns Hopkins Center for Communication Programs (CCP) in partnership with Amref Health Africa, The Busara Center for Behavioral Economics (Busara), and FHI 360. The contents of this website are the sole responsibility of CCP. The information provided on this website does not necessarily reflect the views of USAID, the United States Government, or the Johns Hopkins University. Read our full Security, Privacy, and Copyright Policies.

USAID

Acceptability of Depo-subQ in Uniject, Now Called "Sayana Press"

Community-Based Access to Injectable Contraceptives Toolkit

Community-Based Access to Injectable Contraceptives Toolkit

Search This Toolkit

You are here

Acceptability of Depo-subQ in Uniject, Now Called "Sayana Press"

Community-Based Access to Injectable Contraceptives Toolkit

Community-Based Access to Injectable Contraceptives Toolkit

Search This Toolkit